Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262738 · ClinicalTrials.gov registry record · Phase 4
Misoprostol Dosing in BMI Greater Than 30
A Phase 4 study of Obesity and Pregnancy Related, sponsored by University of Texas at Austin.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT05262738: Completed Phase 4 study of Obesity and Pregnancy Related, sponsored by University of Texas at Austin.
NCT05262738 is a Phase 4 study of Obesity and Pregnancy Related that has completed, run by University of Texas at Austin. The registered enrollment target is 180 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05262738, a Phase 4 study of Obesity and Pregnancy Related, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are performing a randomized controlled-trial investigating if 50mcg (compared to 25 mcg) of vaginal misoprostol reduces the time from induction start to delivery in obese women.
Conditions Studied
Interventions
- DRUG 50 Micrograms Vaginal Misoprostol (Intervention)
- DRUG 25 Micrograms Vaginal Misoprostol (Control)
Study Locations (1)
Texas
- University of Texas at Austin Dell Medical School, Department of Women's Health - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2023-07-17 |
| Phase | Phase 4 |
What the finished NCT05262738 record still lists
NCT05262738 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which 50 Micrograms Vaginal Misoprostol (Intervention) is the first listed.
NCT05262738 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05262738 about?
NCT05262738 is a clinical study titled "Misoprostol Dosing in BMI Greater Than 30". The investigators are performing a randomized controlled-trial investigating if 50mcg (compared to 25 mcg) of vaginal misoprostol reduces the time from induction start to delivery in obese women.
What is the current status of trial NCT05262738?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2022-06-01. Estimated completion is 2023-07-17.
What conditions does trial NCT05262738 study?
This clinical trial studies the following conditions: Obesity, Pregnancy Related, Labor Onset and Length Abnormalities.
What interventions are being tested in trial NCT05262738?
The interventions under investigation include: 50 Micrograms Vaginal Misoprostol (Intervention) (DRUG), 25 Micrograms Vaginal Misoprostol (Control) (DRUG).
Who is sponsoring clinical trial NCT05262738?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05262738 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05262738's enrollment target sits among peer trials
180 339th of 1053 higher than 709 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI